目前国际间用大剂量维他命C静脉注射的治疗研究报导
可以参考这连结
https://ccforum.biomedcentral.com/articles/10.1186/s13054-020-02851-4
希望台湾能赶紧加入这方面的研究
这或许需要政府的主导带领
原文是英文
我用goolge翻译翻成中文，附在每段原文后，给大家方便参考对照...
标题:
A new clinical trial to test high-dose vitamin C in patients with COVID-19
一项新的临床试验，用于在COVID-19患者中测试大剂量维生素C
作者:
Anitra C. Carr
With the 2019 novel coronavirus (2019-nCoV) outbreak now spreading across the world, people are seeking ways in which to potentially protect themselves from the virus or to alleviate its effects once caught. One such means that is being touted online and in the media is vitamin C.
随着2019年新颖的冠状病毒（2019-nCoV）爆发在全球范围内蔓延，人们正在寻找潜在的方法来保护自己免受病毒感染或减轻其感染后的影响。维生素C是一种在网上和媒体上吹捧的手段
Vitamin C is best known for its antioxidant properties, being able to scavenge damaging reactive oxygen species, thus protecting the body’s cells and tissues from oxidative damage and dysfunction. However, the vitamin also has numerous other important functions within the body, many of which are known to support healthy immune function. During infection, vitamin C levels can become depleted and a person’s requirement for vitamin C increases with the severity of the infection [1]. In severe cases, this
may require intravenous administration of gram doses in order to achieve high enough levels in the body to compensate for the enhanced turnover of the vitamin.
维生素C以其抗氧化特性而闻名，能够清除有害的活性氧，从而保护人体的细胞和组织免受氧化损伤和功能障碍。但是，维生素在体内还具有许多其他重要功能，其中许多功能都可以支持健康的免疫功能。在感染过程中，维生素C含量可能会耗尽，并且随着感染程度的增加，人们对维生素C的需求也会增加[1]。在严重的情况下，这可能需要静脉内注射克剂量的药物，以达到体内足够高的水平，以补偿增加的维生素周转率。
As of February 2020, the clinical characteristics of patients hospitalized with COVID-19-related pneumonia indicated that 26% were transferred to the ICU because of complications such as ARDS and shock [2]. A recently published RCT carried out in the USA in 167 patients with sepsis-related ARDS indicated that administration of ~ 15 g/day of IV vitamin C for 4 days may decrease mortality in these patients [3]. An earlier IV vitamin C trial of patients admitted to the ICU with pneumonia included
hydrocortisone administration [4], however, systemic corticosteroid treatment has not been shown to have significant benefits in patients with COVID-19 [5].
截至2020年2月，因CODID-19相关性肺炎住院的患者的临床特征表明，
有26％的患者由于ARDS和休克等并发症而被转移至ICU [2]。
最近在美国对167例败血症相关性ARDS患者进行的RCT研究表明，
每天约15克/天的静脉注射维生素C ，4 天可以降低这些患者的死亡率[3]。
较早的时候，是对接受ICU肺炎治疗的患者进行的IV维生素C试验包括氢化可的松给药[4]，然而此方法，尚未显示全身性皮质类固醇治疗对COVID-19患者俱有明显的益处[5]。
Just recently registered on clincialtrials.gov (Identifier: NCT04264533), a new clinical trial to investigate vitamin C infusion for the treatment of severe 2019-nCoV infected pneumonia has begun in Wuhan, China. This is one of the first RCTs to test the effects of IV vitamin C in patients infected with this virus. In this trial, the investigators will treat 140 patients with a placebo control or intravenous vitamin C at a dose of 24?g/day for 7?days. They will assess requirements for mechanical
ventilation and vasopressor drugs, organ failure scores, ICU length of stay and 28-day mortality.
最近在clincialtrials.gov上注册（标识号：NCT04264533），
一项新的临床试验旨在研究维生素C输注治疗严重的2019-nCoV感染性肺炎的治疗方法，
已在中国武汉开始。 这是首批测试静脉注射型维生素C对感染此病毒的患者的影响的
RCT之一。
在该试验中，研究人员将以24克/天的剂量治疗140例安慰剂对照静脉注射维生素C的患者，持续7天。
他们将评估机械通气和血管升压药的需求，器官衰竭评分，ICU住院时间和28天死亡率。
The investigators of the new study hope to complete the trial by the end of September. Although the findings of this trial will be too late for the many thousands of people currently infected with the virus, the study will nevertheless provide valuable information as to the potential mitigation of symptoms by vitamin C during future viral outbreaks.
这项新研究的研究人员希望在9月底前完成试验。 尽管该试验的结果对于目前感染该病毒的成千上万的人来说为时已晚，但该研究仍将提供有价值的信息，说明在未来病毒暴发期间维生素C可能缓解症状。
Availability of data and materials
N/A
References
1.
Carr AC, Rosengrave PC, Bayer S, Chambers S, Mehrtens J, Shaw GM. Hypovitaminosis C and vitamin C deficiency in critically ill patients despite recommended enteral and parenteral intakes. Crit Care. 2017;21:300.
2.
Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y, Zhao Y, Li Y, Wang X, Peng Z. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;323(11):1061-9.
3.
Fowler AA 3rd, Truwit JD, Hite RD, Morris PE, DeWilde C, Priday A, Fisher B, Thacker LR 2nd, Natarajan R, Brophy DF, Sculthorpe R, Nanchal R, Syed A, Sturgill J, Martin GS, Sevransky J, Kashiouris M, Hamman S, Egan KF, Hastings A, Spencer W, Tench S, Mehkri O, Bindas J, Duggal A, Graf J, Zellner S, Yanny L, McPolin C, Hollrith T, Kramer D, Ojielo C, Damm T, Cassity E, Wieliczko A, Halquist M. Effect of vitamin C infusion on organ failure and biomarkers of inflammation and vascular injury in patients with
sepsis and severe acute respiratory failure: the CITRIS-ALI randomized clinical trial. JAMA. 2019;322(13):1261–70.
4.
Kim WY, Jo EJ, Eom JS, Mok J, Kim MH, Kim KU, Park HK, Lee MK, Lee K. Combined vitamin C, hydrocortisone, and thiamine therapy for patients with severe pneumonia who were admitted to the intensive care unit: propensity score-based analysis of a before-after cohort study. J Crit Care. 2018;47:211–8.
5.
Liu K, Fang YY, Deng Y, Liu W, Wang MF, Ma JP, Xiao W, Wang YN, Zhong MH, Li CH, Li GC, Liu HG. Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province. Chin Med J. 2020. https://doi.org/10.1097/CM9.0000000000000744.